SS Innovations International Inc. reported its first-quarter 2025 financial results, revealing a notable increase in quarterly revenue to $5.1 million, up 40.8% from $3.6 million during the same period in 2024. This rise was primarily driven by higher sales of the SSi Mantra 3 unit. The gross profit also saw a significant increase of 49.3%, reaching $1.1 million from $0.7 million in the first quarter of 2024. The company's net loss narrowed to $5.7 million, compared to a net loss of $9.8 million in the previous year. SS Innovations installed 15 SSi Mantra surgical robotic systems during the quarter, a 66.7% increase from the 9 installations in the first quarter of 2024. As of March 31, 2025, the company had a cumulative installed base of 78 units. Additionally, SS Innovations reported having $15.9 million in cash and cash equivalents, excluding restricted cash, with no long-term debt. The company is on track to submit a De Novo application to the U.S. Food and Drug Administration for the SSi Mantra 3 by July 2025 and is pursuing approval in the European Union, aiming for a CE Mark decision by late 2025. SS Innovations recently uplisted to Nasdaq, marking a significant step toward global expansion beyond the seven countries where the SSi Mantra system is already marketed.